ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
내장통 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 5.8%를 나타낼 것으로 예측되고 185억 8,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 통증 관리 분야의 기술 혁신, 비침습적 치료 옵션에 대한 수요 증가, 신흥 시장 및 미개척 기회, 맞춤형 의약품 접근법, 디지털 헬스 솔루션 통합 등에 기인할 수 있습니다. 예측 기간의 주요 동향에는 멀티모달 통증 관리로의 전환, 대체 요법에 대한 강조 증가, 특정 통증 유형을 위한 표적 치료의 부상, 통증 관리에서 원격의료의 역할 확대, 그리고 통증 평가에 인공지능 통합 등이 포함됩니다.
향후 5년간 5.8% 성장 전망은 이전 예측 대비 0.2% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향 때문입니다. 무역 긴장은 아일랜드와 벨기에에서 개발된 신경조절 장치 및 표적 진통제 주입 펌프 가격 상승을 초래하여 미국 통증 관리에 차질을 빚을 수 있으며, 이는 환자 고통 장기화와 만성 통증 클리닉 비용 증가로 이어질 수 있습니다. 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 효과는 더욱 광범위하게 될 것입니다.
진통제에 대한 수요 증가는 향후 내장통 시장 확장을 촉진할 것으로 예상됩니다. 진통제는 뇌의 통증 신호 인식을 감축하거나 차단하여 통증을 완화하는 약물입니다. 이러한 약물은 신경계에 작용하여 내부 장기로부터의 통증 신호를 조절함으로써 내장통 관리에 도움을 줍니다. 예를 들어, 2024년 4월 영국 주간의학 잡지 New England Journal of Medicine은 2023년 12월까지 5만 3,600명 이상의 임상의가 부프레노르핀을 처방하고 2022년 12월에 비해 1만 1,500명의 처방이 증가하고 있다고 보고했습니다. 이와 같이 진통제에 대한 수요 증가가 내장통 시장의 성장을 뒷받침하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 내장통 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 내장통 시장 : 성장률 분석
세계의 내장통 시장 실적 : 규모와 성장(2019-2024년)
세계의 내장통 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 내장통 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 내장통 시장 : 약제 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
칼슘 채널 차단제
비스테로이드성 항염증제(NSAID)
기타 약물 클래스
세계의 내장통 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
간질성 방광염
크론병
과민성 장 증후군
만성 전립선염
기타 적응증
세계의 내장통 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
홈케어
전문 클리닉
기타 최종 사용자
세계의 내장통 시장, 칼슘 채널 차단제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 내장통 시장, 기타 약물 클래스 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
오피오이드
삼환계 항우울제(TCA)
세로토닌 및 노르에피네프린 재흡수 억제제(SNRI)
제7장 지역별 및 국가별 분석
세계의 내장통 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 내장통 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
내장통 시장 : 경쟁 구도
내장통 시장 : 기업 프로파일
Walgreens Boots Alliance Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
AbbVie Inc.
Novartis AG
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca PLC
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd.
Mylan NV
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Perrigo Company PLC
Dr. Reddy's Laboratories Ltd.
Endo International PLC
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
내장통 시장(2029년) : 새로운 기회를 제공하는 국가
내장통 시장(2029년) : 새로운 기회를 제공하는 부문
내장통 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Visceral pain originates from internal organs such as the stomach, bladder, uterus, or rectum and can stem from factors such as inflammation, menstrual cramps, organ swelling, blockages, reduced blood flow, or tumors, particularly in the pelvis or abdomen, often accompanied by symptoms such as nausea, sweating, or increased heart rate.
The principal drug classes for treating visceral pain include calcium channel blockers (CCBs), nonsteroidal anti-inflammatories (NSAIDs), and others. CCBs regulate calcium ion movement into heart and blood vessel cells, with indications spanning interstitial cystitis, Crohn's disease, irritable bowel syndrome, chronic prostatitis, and more. These medications are employed across various end-user settings including hospitals, homecare, specialty clinics, among others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The visceral pain market research report is one of a series of new reports from The Business Research Company that provides visceral pain market statistics, including visceral pain industry global market size, regional shares, competitors with a visceral pain market share, detailed visceral pain market segments, market trends, and opportunities, and any further data you may need to thrive in the visceral pain industry. This visceral pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The visceral pain market size has grown strongly in recent years. It will grow from $13.84 billion in 2024 to $14.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to aging population, increased incidence of chronic diseases, advances in medical research, expansion of healthcare infrastructure, rising awareness and diagnosis rates.
The visceral pain market size is expected to see strong growth in the next few years. It will grow to $18.58 billion in 2029 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to technological innovations in pain management, growing demand for non-invasive treatment options, emerging markets and untapped opportunities, personalized medicine approaches, integration of digital health solutions. Major trends in the forecast period include shift towards multimodal pain management, increasing emphasis on alternative therapies, rise of targeted therapies for specific pain types, growing role of telemedicine in pain management, integration of artificial intelligence in pain assessment.
The forecast of 5.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pain management by inflating prices of neuromodulation devices and targeted analgesic infusion pumps developed in Ireland and Belgium, resulting in prolonged patient suffering and higher chronic pain clinic costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing demand for analgesics is anticipated to drive the expansion of the visceral pain market in the future. Analgesics are medications that relieve pain by reducing or blocking the brain's perception of pain signals. These medications help manage visceral pain by acting on the nervous system to modulate pain signals from internal organs. For example, in April 2024, the New England Journal of Medicine, a UK-based weekly medical journal, reported that over 53,600 clinicians were prescribing buprenorphine by December 2023, marking an increase of 11,500 prescribers compared to December 2022. Thus, the rising demand for analgesics is fueling the growth of the visceral pain market.
Prominent companies in the visceral pain market are dedicated to developing innovative products such as NHE3 Inhibitors to offer dependable solutions to consumers. NHE3 inhibitors constitute a class of medications that function by inhibiting the Sodium-Proton-Exchanger subtype 3 (NHE3) in the gastrointestinal tract. For example, in April 2022, Ardelyx, a US-based biopharmaceutical firm, introduced an NHE3 Inhibitor medication called IBSRELA. This groundbreaking treatment targets adults with irritable bowel syndrome with constipation (IBS-C), acting on the Sodium-Hydrogen Exchanger 3 (NHE3) in the small intestine and colon. Preclinical studies have demonstrated its efficacy in reducing abdominal pain by alleviating visceral hypersensitivity and intestinal permeability.
In April 2023, Marksans Pharma, a pharmaceutical company based in India, acquired Teva Pharmaceuticals' manufacturing facility in India for an undisclosed amount. This acquisition provides Marksans with a 47,597-square-meter facility, allowing it to double its production capacity in India from 8 billion units per year. The increased capacity will facilitate the production of tablets, hard and soft gel capsules, ointments, liquids, and creams. Teva Pharmaceuticals is an Israel-based company that provides treatments for visceral pain.
Major companies operating in the visceral pain market report are Walgreens Boots Alliance Inc., Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co.Inc., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Endo International PLC, Grunenthal GmbH, Glenmark Pharmaceuticals Limited, Hisamitsu Pharmaceutical Co. Ltd., Chromocell Corporation, Addex Therapeutics Ltd.
North America was the largest region in the visceral pain market in 2024. The regions covered in the visceral pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the visceral pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The visceral pain market consists of sales of opioids, anticonvulsants, gabapentin, and pregabalin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Visceral Pain Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on visceral pain market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for visceral pain ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The visceral pain market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Calcium Channel Blockers; Nonsteroidal Anti-Inflammatory (NSAID); Other Drug Classes
2) By Indications: Interstitial Cystitis; Crohn's; Irritable Bowel; Chronic Prostatitis; Other Indications
3) By End Users: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Calcium Channel Blockers: Dihydropyridines; Non-Dihydropyridines
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Visceral Pain Market Characteristics
3. Visceral Pain Market Trends And Strategies
4. Visceral Pain Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Visceral Pain Growth Analysis And Strategic Analysis Framework
5.1. Global Visceral Pain PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Visceral Pain Market Growth Rate Analysis
5.4. Global Visceral Pain Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Visceral Pain Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Visceral Pain Total Addressable Market (TAM)
6. Visceral Pain Market Segmentation
6.1. Global Visceral Pain Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcium Channel Blockers
Nonsteroidal Anti-Inflammatory (NSAID)
Other Drug Classes
6.2. Global Visceral Pain Market, Segmentation By Indications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interstitial Cystitis
Crohn's
Irritable Bowel
Chronic Prostatitis
Other Indications
6.3. Global Visceral Pain Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.4. Global Visceral Pain Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dihydropyridines
Non-Dihydropyridines
6.5. Global Visceral Pain Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAID), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selective COX-2 Inhibitors
Non-Selective NSAIDs
6.6. Global Visceral Pain Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
